The Davos Alzheimer's Collaborative (DAC) has announced a new partnership with PacBio (PACB, Financial) to enhance its North African Dementia Registry (NADR) project. This initiative aims to create a comprehensive multi-omics dataset to further research on Alzheimer's disease and other dementias across diverse populations.
The NADR project is a collaborative effort spearheaded by DAC with contributions from The Institute of Global Health and Human Ecology at The American University in Cairo and the UCL Queen Square Institute of Neurology at University College London. The primary goal is to deepen understanding of the genetic aspects of Alzheimer's and other dementias, focusing on diverse global populations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Pacific Biosciences of California Inc (PACB, Financial) is $2.10 with a high estimate of $3.50 and a low estimate of $1.00. The average target implies an upside of 84.58% from the current price of $1.14. More detailed estimate data can be found on the Pacific Biosciences of California Inc (PACB) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Pacific Biosciences of California Inc's (PACB, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Pacific Biosciences of California Inc (PACB, Financial) in one year is $5.18, suggesting a upside of 354.39% from the current price of $1.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Pacific Biosciences of California Inc (PACB) Summary page.
